Exercise Plus Duloxetine for Knee Osteoarthritis

PHASE2CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

October 7, 2021

Primary Completion Date

August 11, 2025

Study Completion Date

August 11, 2025

Conditions
Knee OsteoarthritisDepression
Interventions
BEHAVIORAL

Aerobic exercise

Participants with symptomatic knee osteoarthritis and depressive symptoms will be enrolled in a progressive walking program designed to reduce pain and disability and improve psychosocial health.

DRUG

Duloxetine

Duloxetine is an FDA-approved selective serotonin and norepinephrine reuptake inhibitor antidepressant approved for the treatment of neuropathic pain in symptomatic knee osteoarthritis as well as depression in adults. Participants with symptomatic knee osteoarthritis and depressive symptoms will receive duloxetine to decrease pain and depression severity to enhance their ability to engage in aerobic exercise.

Trial Locations (1)

21201

University of Maryland School of Medicine, Baltimore

All Listed Sponsors
collaborator

National Institute on Aging (NIA)

NIH

lead

University of Maryland, Baltimore

OTHER

NCT04111627 - Exercise Plus Duloxetine for Knee Osteoarthritis | Biotech Hunter | Biotech Hunter